Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
← catalyst calendarNCT05456685 · readout ≤ 102 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
125actual
Sites
69
Countries
Belgium, Canada, Georgia +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-28 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- High Grade Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
- Drug: Mirvetuximab soravtansine — also filed as MIRV, IGN853
- Drug: Carboplatin
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured Up to 3 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed